Esperion Therape Stock Price, News & Analysis

Esperion (NASDAQ: ESPR) has announced its participation in two major investor conferences in June 2025: the Jefferies Global Healthcare Conference in New York on June 4 at 1:25 p.m. ET, and the Goldman Sachs Global Healthcare Conference in Miami on June 9 at 10:40 a.m. ET.

The company, a commercial stage biopharmaceutical firm, specializes in FDA-approved oral, once-daily, non-statin medicines for patients with cardiovascular disease and elevated LDL-C. Their medications are supported by the CLEAR Cardiovascular Outcomes Trial involving nearly 14,000 patients. Esperion is also developing next-generation ATP citrate lyase inhibitors (ACLYi) and expanding globally through commercial execution and international partnerships.

Esperion (NASDAQ: ESPR) has reached a settlement agreement with Micro Labs USA, Inc. and its affiliate regarding patent litigation over NEXLETOL. The settlement prevents Micro Labs from marketing a generic version of NEXLETOL in the United States before April 19, 2040, except under specific limited circumstances. The agreement resolves the litigation initiated by Esperion in response to Micro Labs' Abbreviated New Drug Application (ANDA). However, patent litigation continues with eight other defendants, including Accord Healthcare, Alkem Laboratories, Aurobindo Pharma, Dr. Reddy's Laboratories, Hetero USA, MSN Pharmaceuticals, Renata Limited, and Sandoz Inc., with no guarantee of preventing generic versions before 2040.

Esperion (NASDAQ: ESPR) has announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference scheduled for May 20, 2025, at 10 a.m. ET. The event will be webcasted and accessible through Esperion's website, with replay available for approximately 90 days after the presentation.

Esperion is a commercial-stage biopharmaceutical company that develops FDA-approved oral, once-daily, non-statin medicines for patients with cardiovascular disease and elevated LDL-C. Their medications are supported by the CLEAR Cardiovascular Outcomes Trial involving nearly 14,000 patients. The company is also advancing its next-generation program focusing on ATP citrate lyase inhibitors (ACLYi) development.

Esperion (NASDAQ: ESPR) has granted 49,300 restricted stock units (RSUs) to 15 new employees under its 2017 Inducement Equity Incentive Plan. The RSUs will vest 25% on the one-year anniversary of the recipient's vesting commencement date, with the remaining 75% vesting in twelve equal quarterly installments thereafter, subject to continued employment. The grants were made as employment inducements under NASDAQ Rule 5635(c)(4).

Esperion is a commercial-stage biopharmaceutical company developing FDA-approved oral, once-daily, non-statin medicines for cardiovascular disease patients with elevated LDL-C. Their medications are supported by the CLEAR Cardiovascular Outcomes Trial involving nearly 14,000 patients. The company is also advancing its next-generation program focusing on ATP citrate lyase inhibitors (ACLYi).

Esperion Therapeutics (NASDAQ: ESPR) has entered into a license and distribution agreement with HLS Therapeutics for exclusive commercialization rights of NEXLETOL and NEXLIZET in Canada. The agreement includes an upfront payment, milestone payments up to $5 million, and tiered royalties on product sales. Esperion will supply the finished product at a profitable transfer price.

The partnership aims to address a significant market, as approximately 2.6 million Canadian adults live with diagnosed heart disease, which is the second leading cause of death in Canada. HLS will handle commercialization, reimbursement, and marketing responsibilities in Canada, while Esperion maintains product supply duties.

Esperion (NASDAQ: ESPR) has announced its participation in the upcoming Citizens Life Sciences Conference scheduled for May 8, 2025, at 12:30 p.m. ET. The event will be webcasted and accessible through Esperion's website, with replay available for approximately 90 days.

Esperion is a commercial-stage biopharmaceutical company known for developing the only FDA-approved oral, once-daily, non-statin medicines for patients with elevated LDL-C and cardiovascular disease risk. Their medications are backed by the CLEAR Cardiovascular Outcomes Trial, involving nearly 14,000 patients.

The company is advancing its next-generation program focusing on ATP citrate lyase inhibitors (ACLYi), leveraging new insights into structure and function to develop highly potent and specific inhibitors with allosteric mechanisms. Esperion aims to expand globally through commercial execution, international partnerships, and pre-clinical pipeline advancement.

Esperion (NASDAQ: ESPR) announced new research for treating Primary Sclerosing Cholangitis (PSC), a rare liver disease, at their R&D Day 2025. The company unveiled lead candidates, including ESP-1336, which are novel allosteric inhibitors of ATP citrate lyase (ACLY) targeting hepatic inflammation and fibrosis.

The preclinical data shows promising results in reducing liver injury, inflammation, and fibrosis across multiple PSC-relevant models. The company's research utilized multi-omics and phenome-wide association studies to identify ACLY mechanisms linked to bile duct injury and PSC progression.

The market opportunity is estimated at over $1 billion annually, with approximately 76,000 diagnosed PSC patients across the U.S. and Europe as of 2024. The program may be eligible for Orphan Drug and Fast Track designations from the FDA.

Esperion (NASDAQ: ESPR) has announced it will release its first quarter 2025 financial results on Tuesday, May 6, 2025, before market opening. The company will host a webcast at 8:00 a.m. ET to discuss the results and provide business updates.

Esperion is a commercial stage biopharmaceutical company that develops and commercializes FDA-approved oral, once-daily, non-statin medicines for patients with cardiovascular disease and elevated LDL-C. Their medications are supported by the CLEAR Cardiovascular Outcomes Trial, which included nearly 14,000 patients.

The company is also advancing its next generation program focusing on ATP citrate lyase inhibitors (ACLYi), utilizing new insights into structure and function for rational drug design of highly potent and specific inhibitors with allosteric mechanisms.